Lineage Cell Therapeutics

(NYSEMKT) LCTX

Current Price$1.46

Market Cap$363.67M

Since IPO (1992)-52%

5 Year-48%

1 Year+218%

1 Month-7%

Lineage Cell Therapeutics Financials at a Glance

Market Cap

$363.67M

Revenue (TTM)

$14.56M

Net Income (TTM)

$63.53M

EPS (TTM)

$-0.28

P/E Ratio

-5.24

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$1.46

Volume

16,961

Open

$1.46

Price

$1.46

Volume

16,961

Open

$1.46

Previous Close

$1.46

Daily Range

$1.46 - $1.50

52-Week Range

$0.42 - $2.09

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$1.46

Volume

16,961

Open

$1.46

Previous Close

$1.46

Daily Range

$1.46 - $1.50

52-Week Range

$0.42 - $2.09

LCTX News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lineage Cell Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Brian M. Culley, MBA

Website

www.lineagecell.com

Headquarters

Carlsbad, CA 92008, US

LCTX Financials

Key Financial Metrics (TTM)

Gross Margin

94%

Operating Margin

-3%

Net Income Margin

-4%

Return on Equity

-103%

Return on Capital

-36%

Return on Assets

-56%

Earnings Yield

-19.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$363.67M

Shares Outstanding

249.09M

Volume

16.96K

Avg. Volume

1.19M

Financials (TTM)

Gross Profit

$13.71M

Operating Income

$21.78M

EBITDA

$21.08M

Operating Cash Flow

$18.92M

Capital Expenditure

$522.00K

Free Cash Flow

$19.44M

Cash & ST Invst.

$55.78M

Total Debt

$2.42M

Lineage Cell Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$6.61M

+130.4%

Gross Profit

$5.84M

+115.3%

Gross Margin

88.42%

N/A

Market Cap

$363.67M

N/A

Market Cap/Employee

$5.20M

N/A

Employees

N/A

Net Income

$851.00K

+126.0%

EBITDA

$6.36M

-28.3%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$53.36M

+17.8%

Accounts Receivable

$1.56M

+144.8%

Inventory

$0.00

N/A

Long Term Debt

$1.57M

+15.0%

Short Term Debt

$853.00K

-26.0%

Return on Assets

-56.43%

N/A

Return on Invested Capital

-36.18%

N/A

Free Cash Flow

$4.99M

+25.7%

Operating Cash Flow

$4.88M

+23.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

FULCFulcrum Therapeutics, Inc.

FULCFulcrum Therapeutics, Inc.$7.02+0.00%

PRTCPureTech Health plc

PRTCPureTech Health plc$16.69-2.00%

BNTCBenitec Biopharma Inc.

BNTCBenitec Biopharma Inc.$12.20+0.16%

AUTLAutolus Therapeutics plc

AUTLAutolus Therapeutics plc$1.64+4.46%

NGNENeurogene Inc.

NGNENeurogene Inc.$28.94+2.55%

ADCTADC Therapeutics S.A.

ADCTADC Therapeutics S.A.$3.76+2.17%

OCGNOcugen, Inc.

OCGNOcugen, Inc.$1.49-19.46%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$108.15+0.13%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$12.96-0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$67.39+0.04%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$48.59-0.04%

NOKNokia

NOKNokia$13.42+0.02%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$46.28+0.02%

IRENIren

IRENIren$54.74+0.11%

Questions About LCTX

What is the current price of Lineage Cell Therapeutics?

Lineage Cell Therapeutics is trading at $1.46 per share.

What is the 52-week range for Lineage Cell Therapeutics?

Over the past 52 weeks, Lineage Cell Therapeutics has traded between $0.43 and $2.09.

How much debt does Lineage Cell Therapeutics have?

As of the most recent reporting period, Lineage Cell Therapeutics reported total debt of $2.42M.

How much cash does Lineage Cell Therapeutics have on hand?

Lineage Cell Therapeutics reported $40.79M in cash and cash equivalents in its most recent financial results.

What is Lineage Cell Therapeutics’s dividend yield?

Lineage Cell Therapeutics does not currently have a dividend yield.

Lineage Cell Therapeutics

Lineage Cell Therapeutics Financials at a Glance

LCTX News

Lineage Cell Revenue Doubles in Q2

Why Lineage Cell Therapeutics Zoomed Higher Today

Why Lineage Cell Therapeutics Stock Is Soaring Today

Why Lineage Cell Therapeutics Stock Popped Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Lineage Cell Therapeutics

LCTX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Lineage Cell Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About LCTX

What is the current price of Lineage Cell Therapeutics?

What is the 52-week range for Lineage Cell Therapeutics?

How much debt does Lineage Cell Therapeutics have?

How much cash does Lineage Cell Therapeutics have on hand?

What is Lineage Cell Therapeutics’s dividend yield?

Premium Investing Services